OCULAR HYPERTENSION AFTER INTRAVITREAL INJECTION OF 2-MG TRIAMCINOLONE
Authors:
- Anthony ObeidAOAnthony Obeid
- Maitri PancholyMPMaitri Pancholy
- Jake GoodmanJGJake Goodman
- Durga BorkarDBDurga Borkar
- Daniel SuDSDaniel Su
- Carl RegilloCRCarl Regillo
- 1 January 2020
- journal article
- research article
- Published by Wolters Kluwer Health in Retina
- Vol. 40 (1) , 75-79
Abstract
Purpose: To report the incidence and course of ocular hypertension after intravitreal injection of 2-mg triamcinolone acetonide (IVT). Methods: In a retrospective, consecutive series, all patients receiving 2-mg IVT at a single institution between March 1, 2012, and March 1, 2017, with a minimum of 3-month follow-up were reviewed. Ocular hypertension was defined as an intraocular pressure (IOP) measurement over 24 mmHg at any follow-up visit after IVT. Patients receiving topical, periocular, or intravitreal corticosteroid other than 2-mg IVT were excluded. Results: A total of 106 eyes in 100 patients receiving at least one injection of 2-mg IVT were included. Eyes received an average of 2.9 injections (range 1–17), and average patient follow-up was 15.1 months (range 3.0–52.5 months). A total of 14 eyes (13.2%) in 14 patients developed ocular hypertension after a median of 1.5 injections (range 1–9) with an average peak IOP of 29 mmHg (range 25–38 mmHg). Overall, a total of 11 eyes (10.4%) had an IOP elevation ≥10 mmHg above baseline at any point after first IVT. In all cases of ocular hypertension, IOP was successfully managed with observation or topical IOP-lowering medication alone; no patients required surgical intervention. Conclusion: Ocular hypertension developed in 13.2% of eyes receiving intravitreal injection of 2-mg triamcinolone acetonide. Incidence of ocular hypertension after 2-mg IVT compares favorably with other intravitreally administered corticosteroids.Keywords
This publication has 20 references indexed in Scilit:
- Dexamethasone Intravitreal Implant in Patients with Macular Edema Related to Branch or Central Retinal Vein OcclusionOphthalmology, 2011
- SUSTAINED ELEVATED INTRAOCULAR PRESSURES AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, RANIBIZUMAB, AND PEGAPTANIBRetina, 2011
- Secondary Ocular Hypertension After Intravitreal Injection with 2 mg or 4 mg of Triamcinolone in Retinal Vein OcclusionJournal of Ocular Pharmacology and Therapeutics, 2010
- Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular EdemaOphthalmology, 2010
- A Randomized Trial Comparing Intravitreal Triamcinolone Acetonide and Focal/Grid Photocoagulation for Diabetic Macular EdemaOphthalmology, 2008
- INTRAVITREAL TRIAMCINOLONE FOR DIABETIC MACULAR EDEMARetina, 2008
- Intravitreal Triamcinolone Acetonide for Diffuse Diabetic Macular Edema: Phase 2 Trial Comparing 4 mg vs 2 mgAmerican Journal of Ophthalmology, 2006
- Intraocular pressure alterations following intravitreal triamcinolone acetonideBritish Journal of Ophthalmology, 2006
- Intraocular Pressure Elevation After Intravitreal Triamcinolone Acetonide InjectionOphthalmology, 2005
- Intravitreal triamcinolone acetonide and intraocular pressureAmerican Journal of Ophthalmology, 2004